Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors-Reference-Cited by-同舟云学术

Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors

Published:2015-10 Issue:40 Volume:94 Page:e1281
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Mehta Shreya,de Reuver Philip R.,Gill Preetjote,Andrici Juliana,D’Urso Lisa,Mittal Anubhav,Pavlakis Nick,Clarke Stephen,Samra Jaswinder S.,Gill Anthony J.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference25 articles.

1. Epidemiology of gastroenteropancreatic neuroendocrine tumours.;Fraenkel;Best Pract Res Clin Gastroenterol,2012

2. Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.;Wei;Ann Surg,2014

3. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.;Fazio;Cancer Treat Rev,2010

4. Clinicopathological features of small nonfunctioning pancreatic neuroendocrine tumours.;Furukori;World J Gastroenterol,2014

5. Advances in diagnosis and treatment of pancreatic neuroendocrine tumors.;Vinik;Endocr Pract,2014

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CXCR4: From Signaling to Clinical Applications in Neuroendocrine Neoplasms;Cancers;2024-05-08

2. Surgical resection of double advanced pancreatic neuroendocrine tumors with multiple renal cell carcinoma associated with von Hippel–Lindau disease;Clinical Journal of Gastroenterology;2024-05-02

3. Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors;Scientific Reports;2024-02-19

4. The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid Cancer;Endocrine Practice;2023-12

5. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting;JNCI: Journal of the National Cancer Institute;2023-05-31